https://mindmedicinelaw.com/briefing/synthetic-psychedelics-and-trd-trials-uncovering-design-flaws-20260703-18587The Psychedelic Journalen2026-07-03T15:03:45.813507+00:00Synthetic Psychedelics and TRD Trials: Uncovering Design Flawssynthetic psychedelics, treatment-resistant depression, TRD trial design, clinical trial limitations, psychedelic research, depression treatment, psychedelic effects, trial methodologieshttps://mindmedicinelaw.com/briefing/ai-in-psychedelic-trials-navigating-legal-risks-20260702-18589The Psychedelic Journalen2026-07-03T15:03:55.210818+00:00AI in Psychedelic Trials: Navigating Legal RisksAI in clinical trials, psychedelic research, legal risks, data privacy, trial participant selection, GDPR compliance, HIPAA regulations, AI bias, ethical standards, AI transparencyhttps://mindmedicinelaw.com/briefing/ketamine-misuse-interventions-clinical-and-policy-implications-20260701-18577The Psychedelic Journalen2026-07-03T15:04:08.357739+00:00Ketamine Misuse Interventions: Clinical and Policy Implicationsketamine misuse, medical interventions, systematic review, therapeutic use, policy implications, treatment protocols, public health, clinical trials, neuroscience, substance misusehttps://mindmedicinelaw.com/briefing/ketamine-s-long-term-anxiolytic-effects-in-female-rats-20260701-18353The Psychedelic Journalen2026-07-02T22:05:09.503105+00:00Ketamine's Long-Term Anxiolytic Effects in Female Ratsketamine research, anxiolytic effects, female rats, oxidative stress, psychiatric treatment, treatment-resistant depression, sex-specific studies, neuroscience, preclinical research, Wistar-Kyoto ratshttps://mindmedicinelaw.com/briefing/psychedelics-role-in-social-cognition-new-insights-20260701-18040The Psychedelic Journalen2026-07-01T22:03:11.723956+00:00Psychedelics' Role in Social Cognition: New Insightspsychedelics, social cognition, psychiatric disorders, serotonergic drugs, MDMA, ketamine, clinical trials, therapeutic interventions, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/esketamine-biomarker-study-in-mdd-a-new-frontier-in-treatment-20260630-18358The Psychedelic Journalen2026-07-03T15:03:28.575218+00:00Esketamine Biomarker Study in MDD: A New Frontier in Treatmentesketamine, major depressive disorder, biomarkers, treatment resistance, multi-omic, personalized medicine, clinical trials, neuroscience, EU Psych-STRATA, machine learninghttps://mindmedicinelaw.com/briefing/ketamine-s-expanding-therapeutic-role-in-psychiatry-and-pain-20260630-18355The Psychedelic Journalen2026-07-02T22:05:33.847152+00:00Ketamine's Expanding Therapeutic Role in Psychiatry and Painketamine, glutamatergic neurotransmission, treatment-resistant depression, chronic pain management, NMDA receptor, synaptic plasticity, neuroinflammation, clinical trials, safety concerns, misuse potentialhttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-brain-circuits-long-term-insights-20260630-18334The Psychedelic Journalen2026-07-02T22:05:25.445940+00:00Psilocybin's Impact on Brain Circuits: Long-Term Insightspsilocybin, brain circuits, fronto-striatal-thalamic, serotonergic pathways, dopaminergic pathways, psychiatric conditions, neuropsychiatric disorders, clinical trials, psychedelic research, brain flexibilityhttps://mindmedicinelaw.com/briefing/implications-of-5-ht2a-and-mglur2-receptor-interaction-findings-20260630-18338The Psychedelic Journalen2026-07-02T22:05:17.658518+00:00Implications of 5-HT2A and mGluR2 Receptor Interaction Findings5-HT2A receptor, mGluR2 receptor, psychedelic research, receptor interaction, neuroscience, clinical trials, LSD, psychedelic mechanisms, therapeutic strategies, receptor colocalizationhttps://mindmedicinelaw.com/briefing/psilocybin-trial-for-anorexia-nervosa-in-adolescents-a-new-frontier-20260630-18337The Psychedelic Journalen2026-07-02T22:05:01.825554+00:00Psilocybin Trial for Anorexia Nervosa in Adolescents: A New Frontierpsilocybin, anorexia nervosa, adolescents, clinical trial, psychiatric treatment, neurobiology, functional MRI, treatment as usual, psychedelic therapy, relapse rateshttps://mindmedicinelaw.com/briefing/esketamine-nasal-spray-efficacy-and-safety-in-trd-20260630-18359The Psychedelic Journalen2026-07-02T22:04:52.764805+00:00Esketamine Nasal Spray: Efficacy and Safety in TRDesketamine nasal spray, treatment-resistant depression, rapid-acting antidepressant, NMDA receptor, clinical trial data, real-world evidence, safety profile, long-term effects, phase 3 trialshttps://mindmedicinelaw.com/briefing/mdma-and-psilocybin-therapy-rules-relaxed-in-2026-20260629-18588The Psychedelic Journalen2026-07-03T15:03:18.790231+00:00MDMA and Psilocybin Therapy Rules Relaxed in 2026MDMA therapy, psilocybin therapy, regulatory changes, psychedelic research, clinical trials, mental health treatment, FDA, EMA, Schedule I substances, psychedelic therapieshttps://mindmedicinelaw.com/briefing/patient-education-in-ketamine-therapies-for-mood-disorders-20260629-18048The Psychedelic Journalen2026-07-01T22:03:19.463321+00:00Patient Education in Ketamine Therapies for Mood Disordersketamine therapy, esketamine treatment, mood disorders, patient education, clinical outcomes, treatment adherence, psychedelic research, mental health, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/ketamine-s-adverse-effects-in-emergency-medicine-20260628-18347The Psychedelic Journalen2026-07-03T15:03:36.081028+00:00Ketamine's Adverse Effects in Emergency Medicineketamine adverse effects, emergency medicine, psycho-perceptual effects, ketamine-induced cystitis, ketamine-associated cholangiopathy, ketamine use disorder, recreational ketamine use, emergency physicians, patient care, clinical management